CoChat

The pro- and anti-tumor roles of mesenchymal stem cells toward BRCA1-IRIS-overexpressing TNBC cells

Open access
Ryan, Daniel, Paul, Bibbin T., Koziol, Jim, ElShamy, Wael M. · 2019 · Breast Cancer Research

The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.

Abstract

To evaluate the cross-talk between BRCA1-IRIS (IRIS)-overexpressing (IRISOE) TNBC cells and tumor-resident mesenchymal stem cells (MSCs) that triggers the aggressiveness or elimination of IRISOE TNBC tumors. We analyzed the effect of silencing or inactivating IRIS on the bi-directional interaction between IRISOE TNBC cells and MSCs on tumor formation and progression. We analyzed the downstream signaling in MSCs induced by IL-6 secreted from IRISOE TNBC cells. We compared the effect of MSCs on the formation and progression of IRIS-proficient and deficient-TNBC cells/tumors using in vitro and in vivo models. Finally, we analyzed the association between IL-6, PTGER2, and PTGER4 overexpression and breast cancer subtype; hormone receptor status; and distant metastasis-free or overall survival. We show high-level IL-6 secreted from IRISOE TNBC cells that enhances expression of its receptor (IL-6R) in MSCs, their proliferation, and migration toward IRISOE, in vitro, and recruitment into IRISOE TNBC tumors, in vivo. In serum-free medium, recombinant IL-6 and the IL-6-rich IRISOE TNBC cell condition media (CM) decreased STAT3 Y705 phosphorylation (p-STAT3 Y705 ) in MSCs. Inhibiting IRIS expression or activity prolonged STAT3 Y705 phosphorylation in MSCs. The interaction with IRISOE TNBC cells skewed MSC differentiation toward prostaglandin E 2 (PGE 2 )-secreting pro-aggressiveness cancer-associated fibroblasts (CAFs). Accordingly, co-injecting human or mouse MSCs with IRISOE TNBC tumor cells promoted the formation of aggressive mammary tumors, high circulating IL-6 and PGE 2 levels, and reduced overall survival. In contrast, IRIS-silenced or inactivated cells showed reduced tumor formation ability, limited MSC recruitment into tumors, reduced circulating IL-6 and PGE 2 levels, and prolonged overall survival. A positive correlation between IL-6, PTGER2, and PTGER4 expression and basal phenotype; ER-negativity; distant metastasis-free and overall survival in basal; or BRCA mutant carriers was observed. Finally, the bi-directional interaction with MSCs triggered death rather than growth of IRIS-silenced TNBC cells, in vitro and in vivo. The IL-6/PGE 2 -positive feedback loop between IRISOE TNBC tumor cells and MSCs enhances tumor aggressiveness. Inhibiting IRIS expression limits TNBC tumor growth and progression through an MSC-induced death of IRIS-silenced/inactivated TNBC cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13058-019-1131-2

Cites

77 of 77 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 IL-6/PGE2 feedback loop between IRISOE TNBC cells and activated MSCs. a Normalized IL-6 level detected using ELISA in CM of HME, IRIS291, and IRIS293 cells expressing siLuc or siHIF-1α exposed 24 h to normoxic or hypoxic conditions. Experiments were done three separate times in triplicates. b Expression of indicated proteins in MSCs exposed to CM from IRIS291, IRIS292, or IRIS293 cells grown under normoxic or hypoxic condition added plus vehicle or anti-IL-6 NeuAb. Fold change in black compares normoxic and hypoxic conditions, and in red compares hypoxia plus vehicle vs. plus IL-6 NeuAb conditions. Experiments were done at least twice. c Top: effects of 10 μM of STAT3 inhibitor; VII, PI3’K/AKT inhibitor; LY294002 and ERK inhibitor; PD98059 on their cognate kinase. Bottom: MTS assay measuring proliferation of MSCs exposed to CM from normoxic or hypoxic IRIS291 or IRIS293 in the presence of vehicle, VII, LY294002, or PD98059. Experiments were done three separate times in triplicates. The level of p-STAT3Y705 in MSCs exposed to vehicle [−] or 30 ng/ml rIL-6 or CM from HME, IRIS291, IRIS292, or IRIS293 cells for 30 min (d), or CM from MDA-231 or MDA-468 expressing si/shCtrl or si/shIRIS or MCF7 or T47D expressing vector or IRIS cDNA for 30 min (e). d, e Experiments were done at least twice. f The level of p-STAT3Y705, total STAT3 or Cyclin D1 in cytoplasm (C) or nuclear/chromatin (N + Ch) fractions of MSCs exposed to vehicle [−] or 30 ng/ml rIL-6 or CM from MDA-231, MDA-468, or MDA-453 expressing si/shCtrl or si/shIRIS for 30 min. Experiments were done at least twice. g Fluorescence IHC for p-STAT3Y705 and CD105 on sections from the core (1–4) or periphery (5–8) of IRIS291 tumors. Scale bar = 100 μm. h Migration in Boyden chambers of MSCs layered in inserts and exposed to HME (1) or IRISOE cells CM plus vehicle (2) or plus IL-6 NeuAb (3). Experiments were done in triplicates three separate times. i Migration in Boyden chambers of MSCs layered in the inserts exposed to vehicle [−], IRIS291 or IRIS293 cell CM containing vehicle, VII, LY294002, or PD98059 (at 10 μM each). Experiments were done three separate times in triplicates. j Inset: normalized PGE2 level secreted from naïve MSCs, HME, IRIS291, or IRIS293 cells as detected using ELISA. Experiments were done three separate times in triplicates. Normalized PGE2 levels secreted from naïve MSCs or MSCs exposed to CM from HME, IRIS291, or IRIS293 cells expressing (48 h) siLuc or siIL-6 and exposed (24 h) to normoxia or hypoxia as detected using ELISA. Experiments were done three separate times in triplicates. k The level of EP2 and EP4 in HME, IRIS291, IRIS292, or IRIS293 cells. Experiments were done at least twice. l Schematic representation of the data represented above
Fig. 1 IL-6/PGE2 feedback loop between IRISOE TNBC cells and activated MSCs. a Normalized IL-6 level detected using ELISA in CM of HME, IRIS291, and IRIS293 cells expressing siLuc or siHIF-1α exposed 24 h to normoxic or hypoxic conditions. Experiments were done three separate times in triplicates. b Expression of indicated proteins in MSCs exposed to CM from IRIS291, IRIS292, or IRIS293 cells grown under normoxic or hypoxic condition added plus vehicle or anti-IL-6 NeuAb. Fold change in black compares normoxic and hypoxic conditions, and in red compares hypoxia plus vehicle vs. plus IL-6 NeuAb conditions. Experiments were done at least twice. c Top: effects of 10 μM of STAT3 inhibitor; VII, PI3’K/AKT inhibitor; LY294002 and ERK inhibitor; PD98059 on their cognate kinase. Bottom: MTS assay measuring proliferation of MSCs exposed to CM from normoxic or hypoxic IRIS291 or IRIS293 in the presence of vehicle, VII, LY294002, or PD98059. Experiments were done three separate times in triplicates. The level of p-STAT3Y705 in MSCs exposed to vehicle [−] or 30 ng/ml rIL-6 or CM from HME, IRIS291, IRIS292, or IRIS293 cells for 30 min (d), or CM from MDA-231 or MDA-468 expressing si/shCtrl or si/shIRIS or MCF7 or T47D expressing vector or IRIS cDNA for 30 min (e). d, e Experiments were done at least twice. f The level of p-STAT3Y705, total STAT3 or Cyclin D1 in cytoplasm (C) or nuclear/chromatin (N + Ch) fractions of MSCs exposed to vehicle [−] or 30 ng/ml rIL-6 or CM from MDA-231, MDA-468, or MDA-453 expressing si/shCtrl or si/shIRIS for 30 min. Experiments were done at least twice. g Fluorescence IHC for p-STAT3Y705 and CD105 on sections from the core (1–4) or periphery (5–8) of IRIS291 tumors. Scale bar = 100 μm. h Migration in Boyden chambers of MSCs layered in inserts and exposed to HME (1) or IRISOE cells CM plus vehicle (2) or plus IL-6 NeuAb (3). Experiments were done in triplicates three separate times. i Migration in Boyden chambers of MSCs layered in the inserts exposed to vehicle [−], IRIS291 or IRIS293 cell CM containing vehicle, VII, LY294002, or PD98059 (at 10 μM each). Experiments were done three separate times in triplicates. j Inset: normalized PGE2 level secreted from naïve MSCs, HME, IRIS291, or IRIS293 cells as detected using ELISA. Experiments were done three separate times in triplicates. Normalized PGE2 levels secreted from naïve MSCs or MSCs exposed to CM from HME, IRIS291, or IRIS293 cells expressing (48 h) siLuc or siIL-6 and exposed (24 h) to normoxia or hypoxia as detected using ELISA. Experiments were done three separate times in triplicates. k The level of EP2 and EP4 in HME, IRIS291, IRIS292, or IRIS293 cells. Experiments were done at least twice. l Schematic representation of the data represented aboveCC BY · PubMed Central
Fig. 2 IL-6-secreting TNBC cells attract IL-6R-expressing/PGE2-secreting MSCs, in the orthotopic model. a Schematic representation of the assays performed. b The volume of orthotopic mammary tumors developed following injection of 2 × 106 cells of MDA-231/shCtrl cells (light blue, n = 5), MDA-231/shIRIS (dark blue, n = 5), MDA-468/shCtrl (yellow, n = 5), and MDA-468/shIRIS (red, n = 5). The inset shows the expression of IRIS in these cells. c The levels of circulating IL-6 (upper) or PGE2 (lower) as detected using ELISA in sera from mice bearing MDA-231/shCtrl or MDA-231/shIRIS and MDA-468/shCtrl, or MDA-468/shIRIS tumors. d FACS analysis of the percentage of IL-6R−CD90−, IL-6R−CD90+, IL-6R+CD90−, or IL-6R−CD90+ cells within MDA-231/shCtrl and MDA-231/shIRIS tumors (upper), or MDA-468/shCtrl and MDA-468/shIRIS tumors (lower). Fluorescence IHC staining of MDA-231/shCtrl or MDA-231/shIRIS tumor sections with CK5 (green), the MSC marker CD90 (red), and IL-6R (yellow). In 3`, 5`, and 9`, arrowheads denote cancer cells and arrows denote MSCs. The asterisk in 8 denotes immune cells (e.g., B cells) or red blood cells non-specific labeling with most likely a subset of secondary antibodies. Scale bars = 100 μm in 1–6 and 7–12 and 50 μm in 3`, 9`, 5`, and 11`
Fig. 2 IL-6-secreting TNBC cells attract IL-6R-expressing/PGE2-secreting MSCs, in the orthotopic model. a Schematic representation of the assays performed. b The volume of orthotopic mammary tumors developed following injection of 2 × 106 cells of MDA-231/shCtrl cells (light blue, n = 5), MDA-231/shIRIS (dark blue, n = 5), MDA-468/shCtrl (yellow, n = 5), and MDA-468/shIRIS (red, n = 5). The inset shows the expression of IRIS in these cells. c The levels of circulating IL-6 (upper) or PGE2 (lower) as detected using ELISA in sera from mice bearing MDA-231/shCtrl or MDA-231/shIRIS and MDA-468/shCtrl, or MDA-468/shIRIS tumors. d FACS analysis of the percentage of IL-6R−CD90−, IL-6R−CD90+, IL-6R+CD90−, or IL-6R−CD90+ cells within MDA-231/shCtrl and MDA-231/shIRIS tumors (upper), or MDA-468/shCtrl and MDA-468/shIRIS tumors (lower). Fluorescence IHC staining of MDA-231/shCtrl or MDA-231/shIRIS tumor sections with CK5 (green), the MSC marker CD90 (red), and IL-6R (yellow). In 3`, 5`, and 9`, arrowheads denote cancer cells and arrows denote MSCs. The asterisk in 8 denotes immune cells (e.g., B cells) or red blood cells non-specific labeling with most likely a subset of secondary antibodies. Scale bars = 100 μm in 1–6 and 7–12 and 50 μm in 3`, 9`, 5`, and 11`CC BY · PubMed Central
Fig. 3 IRIS inactivation suppresses recruitment of the IL-6R-expressing/PGE2-secreting MSCs in an established TNBC orthotopic model. a Schematic representation of the assays performed. b The volume of orthotopic mammary tumors developed following injection of 2 × 106 IRIS291 cells and at ~ 0.5 cm3 intratumorally (i.t.) injected with scrambled (dark blue, n = 5) or IRIS-pep (light blue, n = 5), or 2 × 106 IRIS293 cells and at 0.5 cm3 i.t. injected with scrambled (red, n = 5) or IRIS-pep (yellow, n = 5). c The levels of circulating IL-6 (upper) or PGE2 (lower) as detected using ELISA in mice bearing IRIS291 or IRIS293 tumors treated with scrambled or IRIS-pep. d FACS analysis of the percentage of IL-6R−CD90−, IL-6R−CD90+, IL-6R+CD90−, or IL-6R−CD90+ cells within IRIS291 treated with scrambled or IRIS-pep (upper), as well as IRIS293 treated with scrambled or IRIS-pep (lower). e Fluorescence IHC staining with CK5 (green), the MSC marker CD90 (red), and IL-6R (yellow) of the 5-μm-thick section from IRIS291 tumors treated with scrambled or IRIS-pep as per scheme shown in a. In 3`, 5`, and 9`, arrowheads denote cancer cells and arrows denote MSCs. The asterisk in 8 denotes immune cells (e.g., B cells) or red blood cells non-specific labeling with most likely a subset of secondary antibodies. Scale bars = 100 μm in 1–6 and 7–12 and 50 μm in 3`, 9`, 5`, and 11`
Fig. 3 IRIS inactivation suppresses recruitment of the IL-6R-expressing/PGE2-secreting MSCs in an established TNBC orthotopic model. a Schematic representation of the assays performed. b The volume of orthotopic mammary tumors developed following injection of 2 × 106 IRIS291 cells and at ~ 0.5 cm3 intratumorally (i.t.) injected with scrambled (dark blue, n = 5) or IRIS-pep (light blue, n = 5), or 2 × 106 IRIS293 cells and at 0.5 cm3 i.t. injected with scrambled (red, n = 5) or IRIS-pep (yellow, n = 5). c The levels of circulating IL-6 (upper) or PGE2 (lower) as detected using ELISA in mice bearing IRIS291 or IRIS293 tumors treated with scrambled or IRIS-pep. d FACS analysis of the percentage of IL-6R−CD90−, IL-6R−CD90+, IL-6R+CD90−, or IL-6R−CD90+ cells within IRIS291 treated with scrambled or IRIS-pep (upper), as well as IRIS293 treated with scrambled or IRIS-pep (lower). e Fluorescence IHC staining with CK5 (green), the MSC marker CD90 (red), and IL-6R (yellow) of the 5-μm-thick section from IRIS291 tumors treated with scrambled or IRIS-pep as per scheme shown in a. In 3`, 5`, and 9`, arrowheads denote cancer cells and arrows denote MSCs. The asterisk in 8 denotes immune cells (e.g., B cells) or red blood cells non-specific labeling with most likely a subset of secondary antibodies. Scale bars = 100 μm in 1–6 and 7–12 and 50 μm in 3`, 9`, 5`, and 11`CC BY · PubMed Central
Fig. 4 IL-6-secreting TNBC cells attract IL-6R-expressing/PGE2-secreting MSCs, in the syngeneic model. a Schematic representation of the assays performed. b The volume of syngeneic mammary tumors developed following injection of 1 × 106 cells of 4T1/shCtrl (black, n = 10), 4T1/shIris1 (red, n = 10), or 4T1/shIris2 (blue, n = 10) cells. The inset shows the expression of Iris in these cells. c The levels of circulating IL-6 (upper) or PGE2 (lower) as detected using ELISA in mice bearing 4T1/shCtrl, 4T1/shIris1, or 4T1/shIris2 tumors. d FACS analysis of the percentage of IL-6R−CD29−, IL-6R−CD29+, IL-6R+CD29−, or IL-6R−CD29+ cells within 4T1/shCtrl and 4T1/shIris1 tumors (upper), or 4T1/shCtrl and 4T1/shIris2 tumors (lower). e Fluorescence IHC staining of MDA231/shCtrl or MDA231/shIris1 tumor sections with CK5 (green), the MSC marker CD90 (red) and IL-6R (yellow). In 3`, 5`, and 9`, arrowheads denote cancer cells and arrows denote MSCs. Scale bars = 100 μm in 1–6 and 7–12 and 50 μm in 3`, 9`, 5`, and 11`
Fig. 4 IL-6-secreting TNBC cells attract IL-6R-expressing/PGE2-secreting MSCs, in the syngeneic model. a Schematic representation of the assays performed. b The volume of syngeneic mammary tumors developed following injection of 1 × 106 cells of 4T1/shCtrl (black, n = 10), 4T1/shIris1 (red, n = 10), or 4T1/shIris2 (blue, n = 10) cells. The inset shows the expression of Iris in these cells. c The levels of circulating IL-6 (upper) or PGE2 (lower) as detected using ELISA in mice bearing 4T1/shCtrl, 4T1/shIris1, or 4T1/shIris2 tumors. d FACS analysis of the percentage of IL-6R−CD29−, IL-6R−CD29+, IL-6R+CD29−, or IL-6R−CD29+ cells within 4T1/shCtrl and 4T1/shIris1 tumors (upper), or 4T1/shCtrl and 4T1/shIris2 tumors (lower). e Fluorescence IHC staining of MDA231/shCtrl or MDA231/shIris1 tumor sections with CK5 (green), the MSC marker CD90 (red) and IL-6R (yellow). In 3`, 5`, and 9`, arrowheads denote cancer cells and arrows denote MSCs. Scale bars = 100 μm in 1–6 and 7–12 and 50 μm in 3`, 9`, 5`, and 11`CC BY · PubMed Central
Fig. 5 IRISOE TNBC tumor cells skew MSCs toward the PGE2-secreting fibrogenic fate, in vitro. Percentage of MSCs stained with Oil Red (a), Alizarin Red S (b), and PicroSirius (c) in cultures exposed to HME, IRIS291, IRIS293 cells, MDA-231/shCtrl, MDA-231/shIRIS, MDA-468/shCtrl, and MDA-468/shIRIS cell CM. d The secretion of PGE2 from naïve MSCs (black) or MSCs chemically differentiated to adipogenic, osteogenic, chondrogenic, or fibrogenic fates, before they were exposed to hypoxic HME (blue), hypoxic IRIS291 (orange), hypoxic IRIS292 (yellow), or hypoxic IRIS293 (red) cell CM
Fig. 5 IRISOE TNBC tumor cells skew MSCs toward the PGE2-secreting fibrogenic fate, in vitro. Percentage of MSCs stained with Oil Red (a), Alizarin Red S (b), and PicroSirius (c) in cultures exposed to HME, IRIS291, IRIS293 cells, MDA-231/shCtrl, MDA-231/shIRIS, MDA-468/shCtrl, and MDA-468/shIRIS cell CM. d The secretion of PGE2 from naïve MSCs (black) or MSCs chemically differentiated to adipogenic, osteogenic, chondrogenic, or fibrogenic fates, before they were exposed to hypoxic HME (blue), hypoxic IRIS291 (orange), hypoxic IRIS292 (yellow), or hypoxic IRIS293 (red) cell CMCC BY · PubMed Central
Fig. 6 The opposing roles of MSCs in IRISOE TNBC tumors. a Schematic representation of the assays presented in (b, c). b Tumor volumes during the 10 weeks following injection in the 2nd thoracic mammary gland of athymic mice of 2 × 106 IRIS291 (yellow), 2 × 106 IRIS291 + 2 × 105 human MSCs (red), 2 × 106 IRIS293 (light blue), or 2 × 106 IRIS293 + 2 × 105 human MSCs (dark blue). c Comparison of percentage of survival in athymic mice injected with IRIS291 (upper, black) and IRIS293 alone (lower, black) vs. mice injected with IRIS291 admixed with MSCs (upper, red) or IRIS293 admixed with MSCs (lower, green). d Percentage of GFP+ cells at days 0–8 in cultures of MDA-468/shCtrl cells + MSCs relative to MDA-468/shCtrl cells (black), and MDA-468/shIRIS cells + MSCs relative to MDA-468/shIRIS cells (red). Representative fluorescence and bright field images of MDA-468/shCtrl (e1 and 2), MDA-468/shCtrl + MSCs (e3 and 4), MDA-468/shIRIS (e5 and 6), or MDA-468/shIRIS + MSCs (e7 and 8). Assay was done three different times in four replicates. Scale bar = 400 μm. f Schematic representation of the assays presented in (g, h). g Tumor volumes during the 60 days following injection of athymic mice 2nd thoracic mammary gland with 1 × 106 MDA-231/shCtrl cells (yellow), 1 × 106 MDA-231/shCtrl cells + 1 × 105 human MSCs (red), 1 × 106 MDA-231/shIRIS cells (light blue), and 1 × 106 MDA-231/shIRIS cells + 1 × 105 human MSCs (dark blue). h Upper: comparison of the percentage of survival of mice in g injected with MDA-231/shCrtl (green) and MDA-231/shIRIS (black). Lower: comparison of percentage survival of mice in g injected with MDA-231/shCtrl admixed with MSCs (dashed) or without MSCs (solid). i Schematic representation of the assays presented in (j, k). j Tumor volumes during 40 days following injection of BALB/c mice 2nd thoracic mammary gland with 5 × 105 4T1/shCtrl cells (yellow), 5 × 105 4T1/shCtrl cells + 5 × 104 mouse MSCs (red), 5 × 105 4T1/shIris1 cells (light blue), and 5 × 105 4T1/shIRIS cells + 1 × 104 mouse MSCs (dark blue). k Upper: comparison of the percentage of survival of mice in g injected with 4T1/shCrtl cells (black), 4T1/shIris1 cells (red) or 4T1/shIris2 cells (green). Lower: comparison of the percentage of survival of mice in g injected with 4T1/shCtrl cells admixed with MSCs (red) or without MSCs (blue)
Fig. 6 The opposing roles of MSCs in IRISOE TNBC tumors. a Schematic representation of the assays presented in (b, c). b Tumor volumes during the 10 weeks following injection in the 2nd thoracic mammary gland of athymic mice of 2 × 106 IRIS291 (yellow), 2 × 106 IRIS291 + 2 × 105 human MSCs (red), 2 × 106 IRIS293 (light blue), or 2 × 106 IRIS293 + 2 × 105 human MSCs (dark blue). c Comparison of percentage of survival in athymic mice injected with IRIS291 (upper, black) and IRIS293 alone (lower, black) vs. mice injected with IRIS291 admixed with MSCs (upper, red) or IRIS293 admixed with MSCs (lower, green). d Percentage of GFP+ cells at days 0–8 in cultures of MDA-468/shCtrl cells + MSCs relative to MDA-468/shCtrl cells (black), and MDA-468/shIRIS cells + MSCs relative to MDA-468/shIRIS cells (red). Representative fluorescence and bright field images of MDA-468/shCtrl (e1 and 2), MDA-468/shCtrl + MSCs (e3 and 4), MDA-468/shIRIS (e5 and 6), or MDA-468/shIRIS + MSCs (e7 and 8). Assay was done three different times in four replicates. Scale bar = 400 μm. f Schematic representation of the assays presented in (g, h). g Tumor volumes during the 60 days following injection of athymic mice 2nd thoracic mammary gland with 1 × 106 MDA-231/shCtrl cells (yellow), 1 × 106 MDA-231/shCtrl cells + 1 × 105 human MSCs (red), 1 × 106 MDA-231/shIRIS cells (light blue), and 1 × 106 MDA-231/shIRIS cells + 1 × 105 human MSCs (dark blue). h Upper: comparison of the percentage of survival of mice in g injected with MDA-231/shCrtl (green) and MDA-231/shIRIS (black). Lower: comparison of percentage survival of mice in g injected with MDA-231/shCtrl admixed with MSCs (dashed) or without MSCs (solid). i Schematic representation of the assays presented in (j, k). j Tumor volumes during 40 days following injection of BALB/c mice 2nd thoracic mammary gland with 5 × 105 4T1/shCtrl cells (yellow), 5 × 105 4T1/shCtrl cells + 5 × 104 mouse MSCs (red), 5 × 105 4T1/shIris1 cells (light blue), and 5 × 105 4T1/shIRIS cells + 1 × 104 mouse MSCs (dark blue). k Upper: comparison of the percentage of survival of mice in g injected with 4T1/shCrtl cells (black), 4T1/shIris1 cells (red) or 4T1/shIris2 cells (green). Lower: comparison of the percentage of survival of mice in g injected with 4T1/shCtrl cells admixed with MSCs (red) or without MSCs (blue)CC BY · PubMed Central
Fig. 7 High levels IL6 plus PTGER2 plus PTGER4 correlate with adverse outcomes in breast cancer patients. a Log2 expression of IL-6 plus PTGER2 plus PTGER4 in basal (n = 357), HER2 (n = 152), luminal A (n = 482), luminal B (n = 289), normal-like (n = 257), and unclassified (n = 344) tumors. b Log2 expression of IL-6 plus PTGER2 plus PTGER4 in ER-negative (n = 395) and ER-positive (n-1225). c Spearman correlation of IL-6 plus PTGER2 plus PTGER4 with the indicated modules (n = 1881). Kaplan-Meier analysis of distant metastasis-free survival in basal tumors (n = 282), overall survival in BRCA tumors (n = 594) of IL-6 plus PTGER2 plus PTGER4 low expressing (d, gray and e, green), or high expressing (d and e, red) breast cancer patients. f Overall summary model of the data presented in the current studies and the proposed mechanism for the MSCs pro- vs. anti-IRISOE TNBC tumors roles
Fig. 7 High levels IL6 plus PTGER2 plus PTGER4 correlate with adverse outcomes in breast cancer patients. a Log2 expression of IL-6 plus PTGER2 plus PTGER4 in basal (n = 357), HER2 (n = 152), luminal A (n = 482), luminal B (n = 289), normal-like (n = 257), and unclassified (n = 344) tumors. b Log2 expression of IL-6 plus PTGER2 plus PTGER4 in ER-negative (n = 395) and ER-positive (n-1225). c Spearman correlation of IL-6 plus PTGER2 plus PTGER4 with the indicated modules (n = 1881). Kaplan-Meier analysis of distant metastasis-free survival in basal tumors (n = 282), overall survival in BRCA tumors (n = 594) of IL-6 plus PTGER2 plus PTGER4 low expressing (d, gray and e, green), or high expressing (d and e, red) breast cancer patients. f Overall summary model of the data presented in the current studies and the proposed mechanism for the MSCs pro- vs. anti-IRISOE TNBC tumors rolesCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 77 references

Research works printed but not linked: 1

  1. Sinha A, Paul BT, Sullivan LM, Sims H, El Bastawisy A, Yousef HF, Zekri AN, Bahnassy AA, ElShamy WM. BRCA1-IRIS overexpression promotes and maintains the tumor initiating phenotype: implications for triple negative breast cancer early lesions. Oncotarget. 2017;8(6):10114–35. · DOI

Cited by

See all 26

Metadata

Authors
Ryan, D., Paul, B. T., Koziol, J., & ElShamy, W. M.
Affiliations
  • San Diego Biomedical Research Institute (US)
  • UConn Health (US)
  • Scripps Research Institute (US)
Corresponding author
ElShamy, Wael M.
Venue
Breast Cancer Research
Published
2019-04-24
Volume
21
Issue
1
Pages
53-53
ISSN
  • 1465-5411 (ISSN-L)
  • 1465-542X
OpenAlex
W2946750486
Cited by
25
References
77
Citations by year
2026: 1 · 2025: 2 · 2024: 4 · 2023: 4 · 2022: 5 · 2021: 5 · 2020: 2 · 2019: 2
FWCI
1.92
Type
journal article
Language
en
Open access
Licence
Locations
  • Breast Cancer Research (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
National Cancer Institute (R01 CA194447)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Keywords
mesenchymal stem cells, triple-negative breast cancer, iris, interleukin-6, IL-6 receptor, STAT3 phosphorylation, prostaglandin E2, EP2 receptor, EP4 receptor, cancer-associated fibroblasts, tumor microenvironment, tumor progression, overall survival, BRCA1 mutation carriers
MeSH terms
Animals, Disease Models, Animal, Female, Humans, Models, Biological, Prognosis, Biomarkers, Tumor, Dinoprostone, Interleukin-6, Gene Expression Regulation, Neoplastic, Alternative Splicing, BRCA1 Protein, Cell Line, Tumor, Mice, Gene Knockdown Techniques, Mesenchymal Stem Cells, Triple Negative Breast Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The pro- and anti-tumor roles of mesenchymal stem cells toward BRCA1-IRIS-overexpressing TNBC cells. https://app.cochat.ai/papers/10.1186/s13058-019-1131-2
The paper
Ryan, D., Paul, B. T., Koziol, J., & ElShamy, W. M. (2019). The pro- and anti-tumor roles of mesenchymal stem cells toward BRCA1-IRIS-overexpressing TNBC cells. Breast Cancer Research. https://doi.org/10.1186/s13058-019-1131-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.